Creation of a long-acting nanoformulated 29,39-dideoxy-39-thiacytidine

Dongwei Guo, Tian Zhou, Mariluz Araínga, Diana Palandri, Nagsen Gautam, Tatiana K Bronich, Yazen Alnouti, JoEllyn M McMillan, Benson J Edagwa, Howard Eliot Gendelman

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: Antiretroviral drug discovery and formulation design will facilitate viral clearance in infectious reservoirs. Although progress has been realized for selected hydrophobic integrase and nonnucleoside reverse transcriptase inhibitors, limited success has been seen to date with hydrophilic nucleosides. To overcome these limitations, hydrophobic long-acting drug nanoparticles were created for the commonly used nucleoside reverse transcriptase inhibitor, lamivudine (29,39-dideoxy-39-thiacytidine, 3TC). Methods: A 2-step synthesis created a slow-release long-acting hydrophobic 3TC. Conjugation of 3TC to a fatty acid created a myristoylated prodrug which was encased into a folate-decorated poloxamer 407. Both in vitro antiretroviral efficacy in human monocyte-derived macrophages and pharmacokinetic profiles in mice were evaluated for the decorated nanoformulated drug. Results: A stable drug formulation was produced by poloxamer encasement that improved monocyte-macrophage uptake, antiretroviral activities, and drug pharmacokinetic profiles over native drug formulations. Conclusions: Sustained release of long-acting antiretroviral therapy is a new therapeutic frontier for HIV/AIDS. 3TC depot formation in monocyte-derived macrophages can be facilitated through stable subcellular internalization and slow drug release.

Original languageEnglish (US)
Pages (from-to)e75-e83
JournalJournal of Acquired Immune Deficiency Syndromes
Volume74
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Drug Compounding
Poloxamer
Reverse Transcriptase Inhibitors
Macrophages
Nucleosides
Pharmacokinetics
Pharmaceutical Preparations
Integrases
Lamivudine
Prodrugs
Drug Discovery
Folic Acid
varespladib methyl
Nanoparticles
Monocytes
Acquired Immunodeficiency Syndrome
Fatty Acids
HIV
Therapeutics

Keywords

  • Folic acid receptor
  • Lamivudine
  • Long-acting antiretroviral therapy
  • Monocyte-macrophages
  • Myristoylation
  • Nanoformulations

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Creation of a long-acting nanoformulated 29,39-dideoxy-39-thiacytidine. / Guo, Dongwei; Zhou, Tian; Araínga, Mariluz; Palandri, Diana; Gautam, Nagsen; Bronich, Tatiana K; Alnouti, Yazen; McMillan, JoEllyn M; Edagwa, Benson J; Gendelman, Howard Eliot.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 74, No. 3, 01.03.2017, p. e75-e83.

Research output: Contribution to journalArticle

@article{549c4fb30d084b5f82ffec03d5fd12f9,
title = "Creation of a long-acting nanoformulated 29,39-dideoxy-39-thiacytidine",
abstract = "Background: Antiretroviral drug discovery and formulation design will facilitate viral clearance in infectious reservoirs. Although progress has been realized for selected hydrophobic integrase and nonnucleoside reverse transcriptase inhibitors, limited success has been seen to date with hydrophilic nucleosides. To overcome these limitations, hydrophobic long-acting drug nanoparticles were created for the commonly used nucleoside reverse transcriptase inhibitor, lamivudine (29,39-dideoxy-39-thiacytidine, 3TC). Methods: A 2-step synthesis created a slow-release long-acting hydrophobic 3TC. Conjugation of 3TC to a fatty acid created a myristoylated prodrug which was encased into a folate-decorated poloxamer 407. Both in vitro antiretroviral efficacy in human monocyte-derived macrophages and pharmacokinetic profiles in mice were evaluated for the decorated nanoformulated drug. Results: A stable drug formulation was produced by poloxamer encasement that improved monocyte-macrophage uptake, antiretroviral activities, and drug pharmacokinetic profiles over native drug formulations. Conclusions: Sustained release of long-acting antiretroviral therapy is a new therapeutic frontier for HIV/AIDS. 3TC depot formation in monocyte-derived macrophages can be facilitated through stable subcellular internalization and slow drug release.",
keywords = "Folic acid receptor, Lamivudine, Long-acting antiretroviral therapy, Monocyte-macrophages, Myristoylation, Nanoformulations",
author = "Dongwei Guo and Tian Zhou and Mariluz Ara{\'i}nga and Diana Palandri and Nagsen Gautam and Bronich, {Tatiana K} and Yazen Alnouti and McMillan, {JoEllyn M} and Edagwa, {Benson J} and Gendelman, {Howard Eliot}",
year = "2017",
month = "3",
day = "1",
doi = "10.1097/QAI.0000000000001170",
language = "English (US)",
volume = "74",
pages = "e75--e83",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Creation of a long-acting nanoformulated 29,39-dideoxy-39-thiacytidine

AU - Guo, Dongwei

AU - Zhou, Tian

AU - Araínga, Mariluz

AU - Palandri, Diana

AU - Gautam, Nagsen

AU - Bronich, Tatiana K

AU - Alnouti, Yazen

AU - McMillan, JoEllyn M

AU - Edagwa, Benson J

AU - Gendelman, Howard Eliot

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Background: Antiretroviral drug discovery and formulation design will facilitate viral clearance in infectious reservoirs. Although progress has been realized for selected hydrophobic integrase and nonnucleoside reverse transcriptase inhibitors, limited success has been seen to date with hydrophilic nucleosides. To overcome these limitations, hydrophobic long-acting drug nanoparticles were created for the commonly used nucleoside reverse transcriptase inhibitor, lamivudine (29,39-dideoxy-39-thiacytidine, 3TC). Methods: A 2-step synthesis created a slow-release long-acting hydrophobic 3TC. Conjugation of 3TC to a fatty acid created a myristoylated prodrug which was encased into a folate-decorated poloxamer 407. Both in vitro antiretroviral efficacy in human monocyte-derived macrophages and pharmacokinetic profiles in mice were evaluated for the decorated nanoformulated drug. Results: A stable drug formulation was produced by poloxamer encasement that improved monocyte-macrophage uptake, antiretroviral activities, and drug pharmacokinetic profiles over native drug formulations. Conclusions: Sustained release of long-acting antiretroviral therapy is a new therapeutic frontier for HIV/AIDS. 3TC depot formation in monocyte-derived macrophages can be facilitated through stable subcellular internalization and slow drug release.

AB - Background: Antiretroviral drug discovery and formulation design will facilitate viral clearance in infectious reservoirs. Although progress has been realized for selected hydrophobic integrase and nonnucleoside reverse transcriptase inhibitors, limited success has been seen to date with hydrophilic nucleosides. To overcome these limitations, hydrophobic long-acting drug nanoparticles were created for the commonly used nucleoside reverse transcriptase inhibitor, lamivudine (29,39-dideoxy-39-thiacytidine, 3TC). Methods: A 2-step synthesis created a slow-release long-acting hydrophobic 3TC. Conjugation of 3TC to a fatty acid created a myristoylated prodrug which was encased into a folate-decorated poloxamer 407. Both in vitro antiretroviral efficacy in human monocyte-derived macrophages and pharmacokinetic profiles in mice were evaluated for the decorated nanoformulated drug. Results: A stable drug formulation was produced by poloxamer encasement that improved monocyte-macrophage uptake, antiretroviral activities, and drug pharmacokinetic profiles over native drug formulations. Conclusions: Sustained release of long-acting antiretroviral therapy is a new therapeutic frontier for HIV/AIDS. 3TC depot formation in monocyte-derived macrophages can be facilitated through stable subcellular internalization and slow drug release.

KW - Folic acid receptor

KW - Lamivudine

KW - Long-acting antiretroviral therapy

KW - Monocyte-macrophages

KW - Myristoylation

KW - Nanoformulations

UR - http://www.scopus.com/inward/record.url?scp=84983514236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983514236&partnerID=8YFLogxK

U2 - 10.1097/QAI.0000000000001170

DO - 10.1097/QAI.0000000000001170

M3 - Article

C2 - 27559685

AN - SCOPUS:84983514236

VL - 74

SP - e75-e83

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 3

ER -